Converting hemodialysis patients from intravenous paricalcitol to intravenous doxercalciferol - A dose equivalency and titration study

Clinical Nephrology

Volumn 70, Issue 4, 2008, Pages 319-324

  Fadem, S Z ^a   Al Saghir, F ^b   Zollner, G ^c   Swan, S ^d  

^a Kidney Associates   (United States)

^b Michigan Kidney Consultants   (United States)

^c Nephrology and Hypertension Associates   (United States)

^d DAVITA CLINICAL RESEARCH   (United States)

Author keywords

Conversion; Cost; Doxercalciferol; iPTH; Paricalcitol

Indexed keywords

CALCIUM; DOXERCALCIFEROL; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE;

ADULT; ARTHRALGIA; ARTICLE; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPARATHYROIDISM; HYPERPHOSPHATEMIA; LIMB PAIN; MALE; MULTICENTER STUDY; PARATHYROID HORMONE BLOOD LEVEL; PATIENT COMPLIANCE; PHASE 4 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL;

EID: 54949139155     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/cnp70319     Document Type: Article

References (10)

1. Ahmed S, O'Neill KD, Hood AF et al. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis. 2001; 37: 1267-1276.
2. Blacher J, Guerin AP, Pannier B et al. Arterial calcifications, arterial stifftiess, and cardiovascular risk in end-stage renal disease. Hypertension. 2001; 38: 938-942.
3. Centers for Medicare and Medicaid Services, Department of Health and Human Services. April 2005 ASP pricing file and ASP NOC file. Available: http://www.cms.hhs.gov/HistPartBDrugPricingFiles/ 02_MMA_Drug_choice.asp.
4. Chen NX, Moe SM. Arterial calcification in diabetes. Curr Diab Rep. 2003; 3: 28-32.
5. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000; 342: 1478-1483.
6. Moe SM, O'Neill KD, Duan D et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int. 2002; 61: 638-647.
7. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification in adult hemodialysis patients. A link between end-stage renal disease and cardiovascular disease? J Am Coll Cardiol. 2002; 39: 695-701.
8. Rodriguez Garcia M, Naves Diaz M, Cannata Andia JB. Bone metabolism, vascular calcifications and mortality: associations beyond mere coincidence. J Nephrol. 2005; 18: 458-463.
9. Wolisi GO, Moe SM. The role of vitamin D in vascular calcification in chronic kidney disease. Semin Dial. 2005; 18: 307-314.
10. Zisman AL, Ghantous W, Schinleber P et al. Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol. Am J Nephrol. 2005; 25: 591-595.